| Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. We show 20 historical shares outstanding datapoints in our ARAV shares outstanding history coverage, used to compute ARAV market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARAV market cap history over the course of time is important for investors
interested in comparing ARAV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARAV versus a peer is one thing; comparing
ARAV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARAV can fluctuate over the course of history.
With this page we aim to empower investors researching ARAV by allowing them to research the ARAV market cap history.